Orexo Us Inc patent expiration

1. Zubsolv patent expiration

ZUBSOLV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8454996 OREXO US INC Pharmaceutical composition for the treatment of acute disorders
Sep, 2019

(4 years ago)

US8658198 OREXO US INC Non-abusable pharmaceutical composition comprising opioids
Dec, 2027

(3 years from now)

US8470361 OREXO US INC Non-abusable pharmaceutical composition comprising opioids
May, 2030

(5 years from now)

US10946010 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US8940330 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US9259421 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US10874661 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US9439900 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US11020388 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US11433066 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)

US11020387 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-713) Aug 10, 2018

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 July, 2013

Treatment: Sublingual administration of a pharmaceutical composition comprising buprenorphine; Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingua...

Dosage: TABLET

How can I launch a generic of ZUBSOLV before it's drug patent expiration?
More Information on Dosage

ZUBSOLV family patents

Family Patents